Pharma companies affected by downturn and exposures to foreign currencies is experiencing a slide in sales from developed markets while seeing a significant growth in sales from emerging markets like Egypt, Russia, Brazil and African markets. For companies like Glenmark, Ranbaxy sales have been up to emerging markets from 20% to as much as 60%. Many pharma will follow suit and will deploy aggressive strategies to introduce several medicines into these markets. Russia, CIS like Ukraine, Kazakhstan, Uzbekistan and Eastern Europe will have high entry barriers with few competitors are ideal for Indian pharma companies to exploit
|11,950 ₹||4950 ₹||4950 ₹||4950 ₹||3950 ₹|
Copyright © 2013 Ibis Research Information Services Pvt Ltd. All Rights Reserved.
Contact : Ibis Research Information Services Pvt Ltd., 28, Rajaji Street, NGO Colony